Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of MN-10-T in osteoporosis at high fracture risk after prior teriparatide
jRCT2031260049Phase 3Recruiting
- Sponsor
- Asahi Kasei Corporation
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, single-arm trial of ZT-034 in osteoporosis, sponsored by Asahi Kasei Corporation. Primary endpoint: Percent change from baseline in lumbar spine bone mineral density. Started May 2026; status: recruiting.
02
Drugs
ZT-034
03
Conditions
osteoporosis
Beyond the preview
Go deeper on jRCT2031260049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260049.